Issue Date: September 24, 2007
Evotec To Acquire Drug Firm Renovis
The German drug discovery firm Evotec has agreed to acquire Renovis, a South San Francisco biotech company focused on pain and inflammatory disease drugs. The all-stock transaction, valued at about $152 million, is expected to create a company with three clinical drug candidates and a strong preclinical pipeline. The proposed deal follows a period of divestment for Evotec. The company sold its technologies business to PerkinElmer this year and recently announced the sale of its chemical development business to Aptuit (C&EN, Sept. 17, page 17).
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society